Anuh Pharma Ltd.
Anuh Pharma Ltd. (ANUHPHR.NS) Stock Competitors & Peer Comparison
See (ANUHPHR.NS) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ANUHPHR.NS | ₹76.52 | +0.07% | 7.7B | 18.35 | ₹4.17 | +1.96% |
| SUNPHARMA.BO | ₹1,843.45 | +0.16% | 4.4T | 40.52 | ₹45.50 | +0.89% |
| SUNPHARMA.NS | ₹1,840.00 | -0.04% | 4.4T | 38.45 | ₹47.86 | +0.89% |
| DIVISLAB.BO | ₹6,805.00 | +0.77% | 1.8T | 70.50 | ₹96.53 | +0.44% |
| DIVISLAB.NS | ₹6,791.00 | +0.56% | 1.8T | 70.32 | ₹96.57 | +0.44% |
| TORNTPHARM.BO | ₹4,539.50 | +1.98% | 1.5T | 71.77 | ₹63.25 | +0.77% |
| TORNTPHARM.NS | ₹4,529.10 | +1.73% | 1.5T | 70.65 | ₹64.11 | +0.77% |
| DRREDDY.BO | ₹1,320.50 | -0.67% | 1.1T | 19.46 | ₹67.84 | +0.61% |
| DRREDDY.NS | ₹1,320.00 | -0.59% | 1.1T | 26.23 | ₹50.33 | +0.61% |
| ZYDUSLIFE.NS | ₹1,087.00 | +0.74% | 1.1T | 21.69 | ₹50.11 | +1.01% |
Stock Comparison
ANUHPHR.NS vs SUNPHARMA.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, SUNPHARMA.BO has a market cap of 4.4T. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while SUNPHARMA.BO trades at ₹1,843.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas SUNPHARMA.BO's P/E ratio is 40.52. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to SUNPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check SUNPHARMA.BO's competition here
ANUHPHR.NS vs SUNPHARMA.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, SUNPHARMA.NS has a market cap of 4.4T. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while SUNPHARMA.NS trades at ₹1,840.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas SUNPHARMA.NS's P/E ratio is 38.45. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to SUNPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check SUNPHARMA.NS's competition here
ANUHPHR.NS vs DIVISLAB.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, DIVISLAB.BO has a market cap of 1.8T. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while DIVISLAB.BO trades at ₹6,805.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas DIVISLAB.BO's P/E ratio is 70.50. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to DIVISLAB.BO's ROE of +0.17%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to DIVISLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check DIVISLAB.BO's competition here
ANUHPHR.NS vs DIVISLAB.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, DIVISLAB.NS has a market cap of 1.8T. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while DIVISLAB.NS trades at ₹6,791.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas DIVISLAB.NS's P/E ratio is 70.32. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to DIVISLAB.NS's ROE of +0.17%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to DIVISLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check DIVISLAB.NS's competition here
ANUHPHR.NS vs TORNTPHARM.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, TORNTPHARM.BO has a market cap of 1.5T. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while TORNTPHARM.BO trades at ₹4,539.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas TORNTPHARM.BO's P/E ratio is 71.77. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to TORNTPHARM.BO's ROE of +0.27%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to TORNTPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check TORNTPHARM.BO's competition here
ANUHPHR.NS vs TORNTPHARM.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, TORNTPHARM.NS has a market cap of 1.5T. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while TORNTPHARM.NS trades at ₹4,529.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas TORNTPHARM.NS's P/E ratio is 70.65. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to TORNTPHARM.NS's ROE of +0.27%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to TORNTPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check TORNTPHARM.NS's competition here
ANUHPHR.NS vs DRREDDY.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, DRREDDY.BO has a market cap of 1.1T. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while DRREDDY.BO trades at ₹1,320.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas DRREDDY.BO's P/E ratio is 19.46. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to DRREDDY.BO's ROE of +0.12%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to DRREDDY.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check DRREDDY.BO's competition here
ANUHPHR.NS vs DRREDDY.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, DRREDDY.NS has a market cap of 1.1T. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while DRREDDY.NS trades at ₹1,320.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas DRREDDY.NS's P/E ratio is 26.23. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to DRREDDY.NS's ROE of +0.12%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to DRREDDY.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check DRREDDY.NS's competition here
ANUHPHR.NS vs ZYDUSLIFE.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, ZYDUSLIFE.NS has a market cap of 1.1T. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while ZYDUSLIFE.NS trades at ₹1,087.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas ZYDUSLIFE.NS's P/E ratio is 21.69. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to ZYDUSLIFE.NS's ROE of +0.20%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to ZYDUSLIFE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check ZYDUSLIFE.NS's competition here
ANUHPHR.NS vs ZYDUSLIFE.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, ZYDUSLIFE.BO has a market cap of 1.1T. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while ZYDUSLIFE.BO trades at ₹1,085.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas ZYDUSLIFE.BO's P/E ratio is 21.67. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to ZYDUSLIFE.BO's ROE of +0.20%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to ZYDUSLIFE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check ZYDUSLIFE.BO's competition here
ANUHPHR.NS vs LUPIN.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, LUPIN.NS has a market cap of 1T. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while LUPIN.NS trades at ₹2,275.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas LUPIN.NS's P/E ratio is 19.52. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to LUPIN.NS's ROE of +0.28%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to LUPIN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check LUPIN.NS's competition here
ANUHPHR.NS vs LUPIN.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, LUPIN.BO has a market cap of 1T. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while LUPIN.BO trades at ₹2,273.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas LUPIN.BO's P/E ratio is 24.09. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to LUPIN.BO's ROE of +0.28%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to LUPIN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check LUPIN.BO's competition here
ANUHPHR.NS vs MANKIND.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, MANKIND.BO has a market cap of 1T. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while MANKIND.BO trades at ₹2,436.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas MANKIND.BO's P/E ratio is 52.76. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to MANKIND.BO's ROE of +0.13%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to MANKIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check MANKIND.BO's competition here
ANUHPHR.NS vs MANKIND.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, MANKIND.NS has a market cap of 1T. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while MANKIND.NS trades at ₹2,434.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas MANKIND.NS's P/E ratio is 52.68. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to MANKIND.NS's ROE of +0.13%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to MANKIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check MANKIND.NS's competition here
ANUHPHR.NS vs AUROPHARMA.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, AUROPHARMA.BO has a market cap of 833.8B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while AUROPHARMA.BO trades at ₹1,435.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas AUROPHARMA.BO's P/E ratio is 24.38. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to AUROPHARMA.BO's ROE of +0.10%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to AUROPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check AUROPHARMA.BO's competition here
ANUHPHR.NS vs AUROPHARMA.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, AUROPHARMA.NS has a market cap of 831.7B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while AUROPHARMA.NS trades at ₹1,431.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas AUROPHARMA.NS's P/E ratio is 23.74. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to AUROPHARMA.NS's ROE of +0.10%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to AUROPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check AUROPHARMA.NS's competition here
ANUHPHR.NS vs LAURUSLABS.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, LAURUSLABS.BO has a market cap of 746B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while LAURUSLABS.BO trades at ₹1,381.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas LAURUSLABS.BO's P/E ratio is 88.24. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to LAURUSLABS.BO's ROE of +0.19%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to LAURUSLABS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check LAURUSLABS.BO's competition here
ANUHPHR.NS vs LAURUSLABS.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, LAURUSLABS.NS has a market cap of 746B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while LAURUSLABS.NS trades at ₹1,381.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas LAURUSLABS.NS's P/E ratio is 88.24. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to LAURUSLABS.NS's ROE of +0.19%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to LAURUSLABS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check LAURUSLABS.NS's competition here
ANUHPHR.NS vs GLENMARK.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, GLENMARK.NS has a market cap of 672.6B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while GLENMARK.NS trades at ₹2,383.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas GLENMARK.NS's P/E ratio is 63.25. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to GLENMARK.NS's ROE of +0.12%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to GLENMARK.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check GLENMARK.NS's competition here
ANUHPHR.NS vs GLENMARK.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, GLENMARK.BO has a market cap of 670.5B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while GLENMARK.BO trades at ₹2,375.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas GLENMARK.BO's P/E ratio is 63.10. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to GLENMARK.BO's ROE of +0.12%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to GLENMARK.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check GLENMARK.BO's competition here
ANUHPHR.NS vs ALKEM.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, ALKEM.BO has a market cap of 655.1B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while ALKEM.BO trades at ₹5,479.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas ALKEM.BO's P/E ratio is 27.61. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to ALKEM.BO's ROE of +0.19%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to ALKEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check ALKEM.BO's competition here
ANUHPHR.NS vs ALKEM.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, ALKEM.NS has a market cap of 654.6B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while ALKEM.NS trades at ₹5,475.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas ALKEM.NS's P/E ratio is 27.59. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to ALKEM.NS's ROE of +0.19%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to ALKEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check ALKEM.NS's competition here
ANUHPHR.NS vs SUVENPHAR.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while SUVENPHAR.NS trades at ₹1,078.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to SUVENPHAR.NS's ROE of +0.09%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to SUVENPHAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check SUVENPHAR.NS's competition here
ANUHPHR.NS vs SUVENPHAR.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while SUVENPHAR.BO trades at ₹1,075.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to SUVENPHAR.BO's ROE of +0.07%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to SUVENPHAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check SUVENPHAR.BO's competition here
ANUHPHR.NS vs IPCALAB.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, IPCALAB.BO has a market cap of 399.2B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while IPCALAB.BO trades at ₹1,573.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas IPCALAB.BO's P/E ratio is 43.90. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to IPCALAB.BO's ROE of +0.12%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to IPCALAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check IPCALAB.BO's competition here
ANUHPHR.NS vs IPCALAB.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, IPCALAB.NS has a market cap of 398.3B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while IPCALAB.NS trades at ₹1,570.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas IPCALAB.NS's P/E ratio is 43.80. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to IPCALAB.NS's ROE of +0.12%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to IPCALAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check IPCALAB.NS's competition here
ANUHPHR.NS vs AJANTPHARM.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, AJANTPHARM.NS has a market cap of 377.9B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while AJANTPHARM.NS trades at ₹3,025.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas AJANTPHARM.NS's P/E ratio is 35.78. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to AJANTPHARM.NS's ROE of +0.26%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to AJANTPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check AJANTPHARM.NS's competition here
ANUHPHR.NS vs AJANTPHARM.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, AJANTPHARM.BO has a market cap of 377.1B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while AJANTPHARM.BO trades at ₹3,018.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas AJANTPHARM.BO's P/E ratio is 37.21. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to AJANTPHARM.BO's ROE of +0.26%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to AJANTPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check AJANTPHARM.BO's competition here
ANUHPHR.NS vs JBCHEPHARM.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, JBCHEPHARM.BO has a market cap of 353.9B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while JBCHEPHARM.BO trades at ₹2,204.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas JBCHEPHARM.BO's P/E ratio is 49.49. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to JBCHEPHARM.BO's ROE of +0.19%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to JBCHEPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check JBCHEPHARM.BO's competition here
ANUHPHR.NS vs JBCHEPHARM.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, JBCHEPHARM.NS has a market cap of 353.2B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while JBCHEPHARM.NS trades at ₹2,200.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas JBCHEPHARM.NS's P/E ratio is 49.61. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to JBCHEPHARM.NS's ROE of +0.19%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to JBCHEPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check JBCHEPHARM.NS's competition here
ANUHPHR.NS vs EMCURE.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, EMCURE.NS has a market cap of 326.9B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while EMCURE.NS trades at ₹1,724.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas EMCURE.NS's P/E ratio is 35.36. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to EMCURE.NS's ROE of +0.20%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to EMCURE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check EMCURE.NS's competition here
ANUHPHR.NS vs WOCKPHARMA.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, WOCKPHARMA.NS has a market cap of 289.3B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while WOCKPHARMA.NS trades at ₹1,780.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas WOCKPHARMA.NS's P/E ratio is 135.78. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to WOCKPHARMA.NS's ROE of +0.05%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to WOCKPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check WOCKPHARMA.NS's competition here
ANUHPHR.NS vs WOCKPHARMA.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, WOCKPHARMA.BO has a market cap of 287.9B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while WOCKPHARMA.BO trades at ₹1,771.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas WOCKPHARMA.BO's P/E ratio is 135.14. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to WOCKPHARMA.BO's ROE of +0.05%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to WOCKPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check WOCKPHARMA.BO's competition here
ANUHPHR.NS vs PEL.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while PEL.NS trades at ₹1,124.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to PEL.NS's ROE of +0.02%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to PEL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check PEL.NS's competition here
ANUHPHR.NS vs PPLPHARMA.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, PPLPHARMA.NS has a market cap of 231.2B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while PPLPHARMA.NS trades at ₹174.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas PPLPHARMA.NS's P/E ratio is -70.93. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to PPLPHARMA.NS's ROE of -0.04%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to PPLPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check PPLPHARMA.NS's competition here
ANUHPHR.NS vs PPLPHARMA.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, PPLPHARMA.BO has a market cap of 230.8B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while PPLPHARMA.BO trades at ₹174.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas PPLPHARMA.BO's P/E ratio is -70.81. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to PPLPHARMA.BO's ROE of -0.04%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to PPLPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check PPLPHARMA.BO's competition here
ANUHPHR.NS vs ASTRAZEN.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, ASTRAZEN.BO has a market cap of 216.4B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while ASTRAZEN.BO trades at ₹8,655.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas ASTRAZEN.BO's P/E ratio is 114.94. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to ASTRAZEN.BO's ROE of +0.23%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to ASTRAZEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check ASTRAZEN.BO's competition here
ANUHPHR.NS vs ASTRAZEN.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, ASTRAZEN.NS has a market cap of 215.3B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while ASTRAZEN.NS trades at ₹8,611.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas ASTRAZEN.NS's P/E ratio is 114.45. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to ASTRAZEN.NS's ROE of +0.23%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to ASTRAZEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check ASTRAZEN.NS's competition here
ANUHPHR.NS vs NEULANDLAB.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, NEULANDLAB.BO has a market cap of 215B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while NEULANDLAB.BO trades at ₹16,759.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas NEULANDLAB.BO's P/E ratio is 59.19. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to NEULANDLAB.BO's ROE of +0.22%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to NEULANDLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check NEULANDLAB.BO's competition here
ANUHPHR.NS vs NEULANDLAB.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, NEULANDLAB.NS has a market cap of 215B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while NEULANDLAB.NS trades at ₹16,755.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas NEULANDLAB.NS's P/E ratio is 59.13. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to NEULANDLAB.NS's ROE of +0.22%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to NEULANDLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check NEULANDLAB.NS's competition here
ANUHPHR.NS vs NATCOPHARM.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, NATCOPHARM.NS has a market cap of 211.2B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while NATCOPHARM.NS trades at ₹1,179.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas NATCOPHARM.NS's P/E ratio is 13.57. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to NATCOPHARM.NS's ROE of +0.20%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to NATCOPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check NATCOPHARM.NS's competition here
ANUHPHR.NS vs NATCOPHARM.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, NATCOPHARM.BO has a market cap of 210.5B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while NATCOPHARM.BO trades at ₹1,175.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas NATCOPHARM.BO's P/E ratio is 13.68. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to NATCOPHARM.BO's ROE of +0.20%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to NATCOPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check NATCOPHARM.BO's competition here
ANUHPHR.NS vs GRANULES.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, GRANULES.NS has a market cap of 195B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while GRANULES.NS trades at ₹787.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas GRANULES.NS's P/E ratio is 32.12. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to GRANULES.NS's ROE of +0.14%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to GRANULES.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check GRANULES.NS's competition here
ANUHPHR.NS vs GRANULES.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, GRANULES.BO has a market cap of 190.2B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while GRANULES.BO trades at ₹783.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas GRANULES.BO's P/E ratio is 34.85. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to GRANULES.BO's ROE of +0.14%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to GRANULES.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check GRANULES.BO's competition here
ANUHPHR.NS vs ERIS.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, ERIS.NS has a market cap of 187.5B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while ERIS.NS trades at ₹1,353.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas ERIS.NS's P/E ratio is 29.94. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to ERIS.NS's ROE of +0.19%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to ERIS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check ERIS.NS's competition here
ANUHPHR.NS vs ERIS.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, ERIS.BO has a market cap of 186.9B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while ERIS.BO trades at ₹1,349.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas ERIS.BO's P/E ratio is 29.76. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to ERIS.BO's ROE of +0.19%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to ERIS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check ERIS.BO's competition here
ANUHPHR.NS vs COHANCE.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, COHANCE.NS has a market cap of 164.5B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while COHANCE.NS trades at ₹429.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas COHANCE.NS's P/E ratio is 92.07. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to COHANCE.NS's ROE of +0.06%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to COHANCE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check COHANCE.NS's competition here
ANUHPHR.NS vs COHANCE.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, COHANCE.BO has a market cap of 163.4B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while COHANCE.BO trades at ₹427.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas COHANCE.BO's P/E ratio is 91.43. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to COHANCE.BO's ROE of +0.06%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to COHANCE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check COHANCE.BO's competition here
ANUHPHR.NS vs JUBLPHARMA.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, JUBLPHARMA.NS has a market cap of 156.8B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while JUBLPHARMA.NS trades at ₹990.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas JUBLPHARMA.NS's P/E ratio is 39.42. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to JUBLPHARMA.NS's ROE of +0.06%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to JUBLPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check JUBLPHARMA.NS's competition here
ANUHPHR.NS vs JUBLPHARMA.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, JUBLPHARMA.BO has a market cap of 156.6B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while JUBLPHARMA.BO trades at ₹988.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas JUBLPHARMA.BO's P/E ratio is 39.42. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to JUBLPHARMA.BO's ROE of +0.06%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to JUBLPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check JUBLPHARMA.BO's competition here
ANUHPHR.NS vs CAPLIPOINT.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, CAPLIPOINT.BO has a market cap of 154.1B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while CAPLIPOINT.BO trades at ₹2,027.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas CAPLIPOINT.BO's P/E ratio is 24.11. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to CAPLIPOINT.BO's ROE of +0.21%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to CAPLIPOINT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check CAPLIPOINT.BO's competition here
ANUHPHR.NS vs CAPLIPOINT.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, CAPLIPOINT.NS has a market cap of 153.9B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while CAPLIPOINT.NS trades at ₹2,025.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas CAPLIPOINT.NS's P/E ratio is 24.08. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to CAPLIPOINT.NS's ROE of +0.21%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to CAPLIPOINT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check CAPLIPOINT.NS's competition here
ANUHPHR.NS vs APLLTD.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, APLLTD.BO has a market cap of 148.6B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while APLLTD.BO trades at ₹755.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas APLLTD.BO's P/E ratio is 22.02. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to APLLTD.BO's ROE of +0.13%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to APLLTD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check APLLTD.BO's competition here
ANUHPHR.NS vs APLLTD.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, APLLTD.NS has a market cap of 147.9B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while APLLTD.NS trades at ₹752.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas APLLTD.NS's P/E ratio is 21.94. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to APLLTD.NS's ROE of +0.13%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to APLLTD.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check APLLTD.NS's competition here
ANUHPHR.NS vs GLS.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while GLS.NS trades at ₹1,086.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to GLS.NS's ROE of +0.21%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to GLS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check GLS.NS's competition here
ANUHPHR.NS vs GLS.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while GLS.BO trades at ₹1,085.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to GLS.BO's ROE of +0.09%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to GLS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check GLS.BO's competition here
ANUHPHR.NS vs ALIVUS.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, ALIVUS.BO has a market cap of 131.9B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while ALIVUS.BO trades at ₹1,074.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas ALIVUS.BO's P/E ratio is 23.39. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to ALIVUS.BO's ROE of +0.21%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to ALIVUS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check ALIVUS.BO's competition here
ANUHPHR.NS vs ALIVUS.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, ALIVUS.NS has a market cap of 131.7B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while ALIVUS.NS trades at ₹1,073.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas ALIVUS.NS's P/E ratio is 23.37. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to ALIVUS.NS's ROE of +0.18%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to ALIVUS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check ALIVUS.NS's competition here
ANUHPHR.NS vs CAPPL.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while CAPPL.BO trades at ₹1,446.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to CAPPL.BO's ROE of +0.10%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to CAPPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check CAPPL.BO's competition here
ANUHPHR.NS vs VIYASH.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, VIYASH.NS has a market cap of 109.1B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while VIYASH.NS trades at ₹250.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas VIYASH.NS's P/E ratio is 62.19. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to VIYASH.NS's ROE of +0.09%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to VIYASH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check VIYASH.NS's competition here
ANUHPHR.NS vs STAR.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, STAR.NS has a market cap of 106.8B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while STAR.NS trades at ₹1,159.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas STAR.NS's P/E ratio is 19.21. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to STAR.NS's ROE of +0.20%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to STAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check STAR.NS's competition here
ANUHPHR.NS vs STAR.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, STAR.BO has a market cap of 106.5B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while STAR.BO trades at ₹1,155.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas STAR.BO's P/E ratio is 19.17. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to STAR.BO's ROE of +0.20%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to STAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check STAR.BO's competition here
ANUHPHR.NS vs PGHL.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, PGHL.NS has a market cap of 104.2B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while PGHL.NS trades at ₹6,275.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas PGHL.NS's P/E ratio is 31.90. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to PGHL.NS's ROE of +0.51%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to PGHL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check PGHL.NS's competition here
ANUHPHR.NS vs PGHL.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, PGHL.BO has a market cap of 103.7B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while PGHL.BO trades at ₹6,245.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas PGHL.BO's P/E ratio is 31.73. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to PGHL.BO's ROE of +0.51%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to PGHL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check PGHL.BO's competition here
ANUHPHR.NS vs SHILPAMED.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, SHILPAMED.NS has a market cap of 96.4B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while SHILPAMED.NS trades at ₹493.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas SHILPAMED.NS's P/E ratio is 39.69. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to SHILPAMED.NS's ROE of +0.10%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to SHILPAMED.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check SHILPAMED.NS's competition here
ANUHPHR.NS vs AKUMS.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, AKUMS.NS has a market cap of 82.1B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while AKUMS.NS trades at ₹536.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas AKUMS.NS's P/E ratio is 32.19. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to AKUMS.NS's ROE of +0.08%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to AKUMS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check AKUMS.NS's competition here
ANUHPHR.NS vs SUDEEPPHRM.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, SUDEEPPHRM.NS has a market cap of 76.2B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while SUDEEPPHRM.NS trades at ₹675.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas SUDEEPPHRM.NS's P/E ratio is 45.27. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to SUDEEPPHRM.NS's ROE of N/A. Regarding short-term risk, ANUHPHR.NS is less volatile compared to SUDEEPPHRM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check SUDEEPPHRM.NS's competition here
ANUHPHR.NS vs SPARC.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, SPARC.NS has a market cap of 72.3B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while SPARC.NS trades at ₹222.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas SPARC.NS's P/E ratio is 4.65. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to SPARC.NS's ROE of +11.09%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to SPARC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check SPARC.NS's competition here
ANUHPHR.NS vs SPARC.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, SPARC.BO has a market cap of 71.9B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while SPARC.BO trades at ₹221.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas SPARC.BO's P/E ratio is 4.63. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to SPARC.BO's ROE of +11.09%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to SPARC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check SPARC.BO's competition here
ANUHPHR.NS vs FDC.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, FDC.BO has a market cap of 69.6B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while FDC.BO trades at ₹427.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas FDC.BO's P/E ratio is 32.15. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to FDC.BO's ROE of +0.09%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to FDC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check FDC.BO's competition here
ANUHPHR.NS vs FDC.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, FDC.NS has a market cap of 68.7B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while FDC.NS trades at ₹422.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas FDC.NS's P/E ratio is 31.68. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to FDC.NS's ROE of +0.09%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to FDC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check FDC.NS's competition here
ANUHPHR.NS vs SUVEN.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, SUVEN.BO has a market cap of 62.1B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while SUVEN.BO trades at ₹267.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas SUVEN.BO's P/E ratio is -21.73. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to SUVEN.BO's ROE of -1.01%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to SUVEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check SUVEN.BO's competition here
ANUHPHR.NS vs SUVEN.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, SUVEN.NS has a market cap of 60B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while SUVEN.NS trades at ₹267.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas SUVEN.NS's P/E ratio is -22.06. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to SUVEN.NS's ROE of -1.01%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to SUVEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check SUVEN.NS's competition here
ANUHPHR.NS vs AARTIPHARM.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, AARTIPHARM.BO has a market cap of 59.5B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while AARTIPHARM.BO trades at ₹656.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas AARTIPHARM.BO's P/E ratio is 34.13. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to AARTIPHARM.BO's ROE of +0.11%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to AARTIPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check AARTIPHARM.BO's competition here
ANUHPHR.NS vs AARTIPHARM.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, AARTIPHARM.NS has a market cap of 59.4B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while AARTIPHARM.NS trades at ₹654.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas AARTIPHARM.NS's P/E ratio is 34.01. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to AARTIPHARM.NS's ROE of +0.11%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to AARTIPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check AARTIPHARM.NS's competition here
ANUHPHR.NS vs SEQUENT.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while SEQUENT.BO trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to SEQUENT.BO's ROE of +0.06%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to SEQUENT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check SEQUENT.BO's competition here
ANUHPHR.NS vs SEQUENT.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while SEQUENT.NS trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to SEQUENT.NS's ROE of +0.06%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to SEQUENT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check SEQUENT.NS's competition here
ANUHPHR.NS vs INNOVACAP.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, INNOVACAP.NS has a market cap of 48.5B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while INNOVACAP.NS trades at ₹848.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas INNOVACAP.NS's P/E ratio is 34.43. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to INNOVACAP.NS's ROE of +0.14%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to INNOVACAP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check INNOVACAP.NS's competition here
ANUHPHR.NS vs SHILPAMED.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, SHILPAMED.BO has a market cap of 48.1B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while SHILPAMED.BO trades at ₹492.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas SHILPAMED.BO's P/E ratio is 39.63. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to SHILPAMED.BO's ROE of +0.10%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to SHILPAMED.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check SHILPAMED.BO's competition here
ANUHPHR.NS vs GUJTHEM.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, GUJTHEM.NS has a market cap of 46.2B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while GUJTHEM.NS trades at ₹424.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas GUJTHEM.NS's P/E ratio is 96.36. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to GUJTHEM.NS's ROE of +0.19%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to GUJTHEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check GUJTHEM.NS's competition here
ANUHPHR.NS vs BLISSGVS.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, BLISSGVS.BO has a market cap of 42B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while BLISSGVS.BO trades at ₹397.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas BLISSGVS.BO's P/E ratio is 33.06. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to BLISSGVS.BO's ROE of +0.12%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to BLISSGVS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check BLISSGVS.BO's competition here
ANUHPHR.NS vs BLISSGVS.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, BLISSGVS.NS has a market cap of 42B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while BLISSGVS.NS trades at ₹397.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas BLISSGVS.NS's P/E ratio is 33.08. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to BLISSGVS.NS's ROE of +0.12%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to BLISSGVS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check BLISSGVS.NS's competition here
ANUHPHR.NS vs ORCHPHARMA.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, ORCHPHARMA.NS has a market cap of 38.8B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while ORCHPHARMA.NS trades at ₹765.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas ORCHPHARMA.NS's P/E ratio is 189.36. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to ORCHPHARMA.NS's ROE of +0.02%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to ORCHPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check ORCHPHARMA.NS's competition here
ANUHPHR.NS vs ORCHPHARMA.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, ORCHPHARMA.BO has a market cap of 38.6B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while ORCHPHARMA.BO trades at ₹761.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas ORCHPHARMA.BO's P/E ratio is 188.58. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to ORCHPHARMA.BO's ROE of +0.02%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to ORCHPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check ORCHPHARMA.BO's competition here
ANUHPHR.NS vs IOLCP.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, IOLCP.BO has a market cap of 38.6B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while IOLCP.BO trades at ₹131.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas IOLCP.BO's P/E ratio is 28.00. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to IOLCP.BO's ROE of +0.08%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to IOLCP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check IOLCP.BO's competition here
ANUHPHR.NS vs IOLCP.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, IOLCP.NS has a market cap of 38.5B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while IOLCP.NS trades at ₹131.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas IOLCP.NS's P/E ratio is 27.93. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to IOLCP.NS's ROE of +0.08%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to IOLCP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check IOLCP.NS's competition here
ANUHPHR.NS vs RPGLIFE.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, RPGLIFE.BO has a market cap of 37B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while RPGLIFE.BO trades at ₹2,240.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas RPGLIFE.BO's P/E ratio is 18.29. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to RPGLIFE.BO's ROE of +0.21%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to RPGLIFE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check RPGLIFE.BO's competition here
ANUHPHR.NS vs RPGLIFE.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, RPGLIFE.NS has a market cap of 37B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while RPGLIFE.NS trades at ₹2,239.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas RPGLIFE.NS's P/E ratio is 18.29. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to RPGLIFE.NS's ROE of +0.21%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to RPGLIFE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check RPGLIFE.NS's competition here
ANUHPHR.NS vs NOVARTIND.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, NOVARTIND.NS has a market cap of 37B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while NOVARTIND.NS trades at ₹1,497.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas NOVARTIND.NS's P/E ratio is 39.63. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to NOVARTIND.NS's ROE of +0.12%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to NOVARTIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check NOVARTIND.NS's competition here
ANUHPHR.NS vs NOVARTIND.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, NOVARTIND.BO has a market cap of 36.7B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while NOVARTIND.BO trades at ₹1,488.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas NOVARTIND.BO's P/E ratio is 39.45. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to NOVARTIND.BO's ROE of +0.12%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to NOVARTIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check NOVARTIND.BO's competition here
ANUHPHR.NS vs AARTIDRUGS.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, AARTIDRUGS.BO has a market cap of 35.8B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while AARTIDRUGS.BO trades at ₹392.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas AARTIDRUGS.BO's P/E ratio is 18.35. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to AARTIDRUGS.BO's ROE of +0.14%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to AARTIDRUGS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check AARTIDRUGS.BO's competition here
ANUHPHR.NS vs AARTIDRUGS.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, AARTIDRUGS.NS has a market cap of 35.7B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while AARTIDRUGS.NS trades at ₹391.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas AARTIDRUGS.NS's P/E ratio is 18.31. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to AARTIDRUGS.NS's ROE of +0.14%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to AARTIDRUGS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check AARTIDRUGS.NS's competition here
ANUHPHR.NS vs GUFICBIO.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, GUFICBIO.BO has a market cap of 32.5B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while GUFICBIO.BO trades at ₹324.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas GUFICBIO.BO's P/E ratio is 65.09. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to GUFICBIO.BO's ROE of +0.08%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to GUFICBIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check GUFICBIO.BO's competition here
ANUHPHR.NS vs GUFICBIO.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, GUFICBIO.NS has a market cap of 32.4B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while GUFICBIO.NS trades at ₹323.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas GUFICBIO.NS's P/E ratio is 64.76. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to GUFICBIO.NS's ROE of +0.08%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to GUFICBIO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check GUFICBIO.NS's competition here
ANUHPHR.NS vs HIKAL.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, HIKAL.NS has a market cap of 27.2B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while HIKAL.NS trades at ₹220.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas HIKAL.NS's P/E ratio is -208.48. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to HIKAL.NS's ROE of -0.01%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to HIKAL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check HIKAL.NS's competition here
ANUHPHR.NS vs HIKAL.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, HIKAL.BO has a market cap of 27.2B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while HIKAL.BO trades at ₹220.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas HIKAL.BO's P/E ratio is 275.50. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to HIKAL.BO's ROE of -0.01%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to HIKAL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check HIKAL.BO's competition here
ANUHPHR.NS vs SOLARA.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, SOLARA.NS has a market cap of 26.2B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while SOLARA.NS trades at ₹544.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas SOLARA.NS's P/E ratio is -327.71. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to SOLARA.NS's ROE of -0.01%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to SOLARA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check SOLARA.NS's competition here
ANUHPHR.NS vs SOLARA.BO Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, SOLARA.BO has a market cap of 26.1B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while SOLARA.BO trades at ₹542.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas SOLARA.BO's P/E ratio is -324.85. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to SOLARA.BO's ROE of -0.01%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to SOLARA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check SOLARA.BO's competition here
ANUHPHR.NS vs UNICHEMLAB.NS Comparison May 2026
ANUHPHR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANUHPHR.NS stands at 7.7B. In comparison, UNICHEMLAB.NS has a market cap of 24.9B. Regarding current trading prices, ANUHPHR.NS is priced at ₹76.52, while UNICHEMLAB.NS trades at ₹353.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANUHPHR.NS currently has a P/E ratio of 18.35, whereas UNICHEMLAB.NS's P/E ratio is 8.45. In terms of profitability, ANUHPHR.NS's ROE is +0.12%, compared to UNICHEMLAB.NS's ROE of +0.10%. Regarding short-term risk, ANUHPHR.NS is less volatile compared to UNICHEMLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANUHPHR.NS.Check UNICHEMLAB.NS's competition here